A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

9T Labs Raises $17M Series A Funding

9T Labs: Composite equipment and software OEM 9T Labs AG announced today that it closed its Series A funding round and raised $17-million USD to help further commercialize the company’s innovative Red Series® Additive Fusion SolutionTM platform for the production of advanced carbon fiber-reinforced thermoplastic (CFRTP) composite parts.

Key investors include the world’s leading 3D printing company Stratasys, the venture capital arm of high-performance thermoplastic composites supplier Solvay SA (Solvay Ventures), as well as VC investors Verve Ventures, ACE & Company, Zürcher Kantonalbank and Wingman Ventures.

9T Labs’ technology platform enables desktop size high-performance structural parts to be produced in CFRTP composites in production volumes ranging from 100 to over 100,000 parts/year. By combining software, 3D printing — offering unexcelled design freedom, part complexity, and control of fiber orientation — with compression molding in matched metal dies – providing rapid cycle times, high production rates, excellent surface finishes and low voids, plus high repeatability and reproducibility (R&R) — 9T Labs’ Red Series platform offers the best of both additive and existing manufacturing to create a more sustainable and high-performance alternative to traditional metal and plastic manufacturing technologies.

It is used by Fortune 500 aerospace companies to lightweight its future mobility programs, by medical corporations to reduce material waste for manufacturing medical instruments and by the leisure and luxury industry to provide consumer products with increased functionality. The global 3D printing market is predicted to grow at a compounded annual growth rate (CAGR) of 25% to exceed a value of $100-billion USD by 2030 in the $2-trillion USD global parts manufacturing segment.

9T Labs has combined the simplicity of 3D printing with the strength of continuous carbon fiber composites, and that’s an exciting development for our industry,” said Adam Pawloski, VP Manufacturing Solutions at Stratasys. “Their Additive Fusion Technology leverages the benefits of printing, automated tape laying, and compression molding to deliver fully dense parts with multidirectional reinforcement. Moreover, this technology scales to the volumes of production parts needed by serial manufacturers. The end result is a solution with the potential to dramatically shift the industry away from metal and towards composite parts.”

“As a leading supplier of thermoplastic composites technologies, we are excited to contribute our materials expertise to help accelerate 9T Labs’ developments in the 3D printing space to produce structural composite parts,” adds Fabrizio Ponte, head of Thermoplastic Composites Platform, Solvay SA.

Following the investment round, John Hartner, former Chief Executive Officer of ExOne (Pittsburgh, PA, USA) will join 9T Labs’ board of director as chairman. Hartner is an experienced leader with more than 30 years’ involvement in the automation, semiconductor, clean tech, and 3D printing industries. “I have been impressed by the company’s unique solution and am very excited to help the team to bring this technology to manufacturing companies around the world” notes Hartner.

The money raised during the Series A investment round will be used to fund the next phase of growth at 9T Labs to help its customers ramp up their applications to mass volumes, complement the current material portfolio, and develop future technology platforms. “This round of investment and the combined expertise with our partners will allow us to make the next big leap in commercialization and fulfilling our mission to enable widespread replacement of metal parts with fully recyclable high-performance carbon composite materials,” adds Martin Eichenhofer, 9T Labs co-founder and CEO.

“Through this support, we will be able to demonstrate things we could not have imagined 10 years ago.”

Source9T Labs
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.
The investment will allow ROM InWest to further distribute its fall detection product globally.
Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”
Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.

By using this website you agree to accept Medical Device News Magazine Privacy Policy